What's behind Hims & Hers Health's latest 3.1% stock pullback?

Traders Union
All News
Stocks
Hims & hers slides 3.09% today

Highlights

Hims & Hers Health reported Q2 revenue growth of 38% year over year with nearly 3 million subscribers and raised its 2030 targets to over $6.5 billion revenue and $1.3 billion adjusted EBITDA.
The company is pursuing U.S. market momentum and international expansion through GLP-1 partnerships while facing lawsuits regarding privacy, billing, and securities fraud and ongoing margin and regulatory pressures.
Shares of Hims & Hers Health last traded at $28.88, down 3.09%, with mixed momentum signals and an expected five-day range of $27.52 to $30.23.

Revenue surge tempered by lawsuits and ongoing margin headwinds

Hims & Hers Health recorded a 38% year-over-year increase in revenue for Q2 and nearly 3 million subscribers, driven by U.S. market momentum and international expansion through GLP-1 partnerships. The company raised its financial outlook, targeting over $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. Multiple lawsuits related to privacy, billing practices, and securities fraud remain ongoing, along with noted margin and regulatory pressures, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes the recent selloff despite robust revenue gains and improved guidance. He believes ongoing lawsuits and persistent regulatory, margin, and technical headwinds continue to undermine investor confidence. The technical structure reveals conflicting momentum, as heavy selling pressure dominates even with a bullish longer-term tilt. Legal and privacy risks may invalidate upside scenarios and further volatility is likely until regulatory clarity improves. "Short-term buyers may find opportunities, but I remain cautious until margin and litigation pressures subside," Kharitonov says.

Viktoras Karapetjanc, expert at Traders Union, sees strong fundamental progress and a compelling growth narrative. He highlights the 38% revenue surge, international expansion, and raised long-term financial targets as signs the bullish structure remains intact. Market action was pressured, but core drivers still point to further upside as legal hurdles are resolved. "I view the current dip as a constructive setup for longer-term gains — Hims & Hers offers multiple opportunities within a well-defined range," says Karapetjanc.

Parshwa Turakhiya, analyst, observes mixed signals in the short term as sellers control momentum despite supportive sentiment indicators. He notes price action locked between key moving averages, with buyers still holding ground near the lower end of the trading corridor. Volatility and divergence across technicals suggest nimble trading strategies are favored. "Sideways scenarios dominate, but a quick break above $29.14 could offer attractive short-term setups for active traders," Turakhiya says.

Mixed momentum as technicals signal short-term weakness amid longer-term resilience

Hims & Hers Health is trading above its 20-day and 200-day moving averages at $28.49 and $27.62, but below its 50-day moving average at $29.41. This arrangement suggests short-term strength, medium-term pressure from sellers, and a positive longer-term trend, with the near-term ceiling set at $29.14 and the floor at $28.49. The Ichimoku Kijun at $29.65 currently acts as resistance and confirms a bullish long-term alignment. Momentum indicators are mixed: MACD signals strong selling pressure, while the Average Directional Index (ADX) remains neutral. Relative Strength Index (RSI) and Stochastic RSI both point to buying conditions, and Commodity Channel Index (CCI) and Bull/Bear Power (BBP) highlight overbought territory; BBP’s value at 2.06 shows buyers dominate intraday momentum. Awesome Oscillator is neutral. The stock last traded at $28.88, down $0.92 or 3.09%. It opened with a downside gap of about $0.57, or 1.91%, and currently sits near the intraday low with volatility at 6.45%. This suggests persistent pressure after the open, and momentum signals present a notable divergence.

Earlier, analysts noted that Hims & Hers Health maintained technical strength while facing heightened litigation risks and regulatory uncertainty. The current environment adds further complexity as margin pressures and persistent selling dominate short- and medium-term action, making the $29.14 resistance a key level to watch for any potential shift in trend.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.